Literature DB >> 25581535

Meeting report VLPNPV: Session 5: Plant based technology.

Lydia R Meador1, Tsafrir S Mor.   

Abstract

The VLPNPV 2014 Conference that was convened at the Salk institute was the second conference of its kind to focus on advances in production, purification, and delivery of virus-like particles (VLPs) and nanoparticles. Many exciting developments were reported and discussed in this interdisciplinary arena, but here we report specifically on the contributions of plant-based platforms to VLP vaccine technology as reported in the section of the conference devoted to the topic as well in additional presentations throughout the meeting. The increasing popularity of plant production platforms is due to their lower cost, scalability, and lack of contaminating animal pathogens seen with other systems. Reports include production of complex VLPs consisting of 4 proteins expressed at finely-tuned expression levels, a prime-boost strategy for HIV vaccination using plant-made VLPs and a live viral vector, and the characterization and development of plant viral nanoparticles for use in cancer vaccines, drug delivery, and bioimaging.

Entities:  

Keywords:  Ab, antibody; BPV, bovine papillomavirus; BTV, Bluetongue virus; CPMV, cowpea mosaic virus; ELISA, enzyme-linked immunosorbent assay; HBV, Hepatitis B virus; HER2, human epidermal growth factor receptor 2 (also called c-ErbB-2); HIV, human immunodeficiency virus; HIV-1; HT, HyperTrans; Hepatitis B core antigen; Ig, immunoglobulin; MPR, membrane proximal region; NPV, nano-particle vaccine; PEG, polyethylene glycol; PVX, potato virus X; SNP, spherical nanoparticle; TMV, tobacco mosaic virus; UTR, untranslated region; VLP, virus-like particle; VNP, viral nanoparticle; bluetongue virus; c-Erbb-2 (human epidermal growth factor receptor 2); cowpea mosaic virus; i.p., intraperitoneal; live viral vectors; potato virus X; tobacco mosaic virus; viral nanoparticles; virus-like particles

Mesh:

Substances:

Year:  2014        PMID: 25581535      PMCID: PMC5443066          DOI: 10.4161/21645515.2014.979693

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  61 in total

1.  Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.

Authors:  Nobuyuki Matoba; Tagan A Griffin; Michele Mittman; Jeffrey D Doran; Annette Alfsen; David C Montefiori; Carl V Hanson; Morgane Bomsel; Tsafrir S Mor
Journal:  Curr HIV Res       Date:  2008-05       Impact factor: 1.581

Review 2.  Virus-like particles produced in plants as potential vaccines.

Authors:  Nunzia Scotti; Edward P Rybicki
Journal:  Expert Rev Vaccines       Date:  2013-02       Impact factor: 5.217

Review 3.  The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza.

Authors:  Marc-André D'Aoust; Manon M-J Couture; Nathalie Charland; Sonia Trépanier; Nathalie Landry; Frédéric Ors; Louis-P Vézina
Journal:  Plant Biotechnol J       Date:  2010-02-18       Impact factor: 9.803

Review 4.  Applications of viral nanoparticles in medicine.

Authors:  Ibrahim Yildiz; Sourabh Shukla; Nicole F Steinmetz
Journal:  Curr Opin Biotechnol       Date:  2011-05-16       Impact factor: 9.740

5.  Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants.

Authors:  Keith Saunders; Frank Sainsbury; George P Lomonossoff
Journal:  Virology       Date:  2009-09-05       Impact factor: 3.616

6.  Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo.

Authors:  Pratik Singh; Duane Prasuhn; Robert M Yeh; Giuseppe Destito; Chris S Rae; Kent Osborn; M G Finn; Marianne Manchester
Journal:  J Control Release       Date:  2007-04-13       Impact factor: 9.776

7.  Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

Authors:  Amy W Chung; Musie Ghebremichael; Hannah Robinson; Eric Brown; Ickwon Choi; Sophie Lane; Anne-Sophie Dugast; Matthew K Schoen; Morgane Rolland; Todd J Suscovich; Alison E Mahan; Larry Liao; Hendrik Streeck; Charla Andrews; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Mark S de Souza; Jaranit Kaewkungwal; Punnee Pitisuttithum; Donald Francis; Nelson L Michael; Jerome H Kim; Chris Bailey-Kellogg; Margaret E Ackerman; Galit Alter
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

8.  Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Authors:  Nicole L Yates; Hua-Xin Liao; Youyi Fong; Allan deCamp; Nathan A Vandergrift; William T Williams; S Munir Alam; Guido Ferrari; Zhi-yong Yang; Kelly E Seaton; Phillip W Berman; Michael D Alpert; David T Evans; Robert J O'Connell; Donald Francis; Faruk Sinangil; Carter Lee; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Abraham Pinter; Susan Zolla-Pazner; Peter B Gilbert; Gary J Nabel; Nelson L Michael; Jerome H Kim; David C Montefiori; Barton F Haynes; Georgia D Tomaras
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

9.  Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.

Authors:  Esther D Quakkelaar; Anke Redeker; Elias K Haddad; Alexandre Harari; Stella Mayo McCaughey; Thomas Duhen; Abdelali Filali-Mouhim; Jean-Philippe Goulet; Nikki M Loof; Ferry Ossendorp; Beatriz Perdiguero; Paul Heinen; Carmen E Gomez; Karen V Kibler; David M Koelle; Rafick P Sékaly; Federica Sallusto; Antonio Lanzavecchia; Giuseppe Pantaleo; Mariano Esteban; Jim Tartaglia; Bertram L Jacobs; Cornelis J M Melief
Journal:  PLoS One       Date:  2011-02-15       Impact factor: 3.240

10.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

View more
  1 in total

Review 1.  A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus.

Authors:  Sergio Rosales-Mendoza; Ricardo Nieto-Gómez; Carlos Angulo
Journal:  Front Immunol       Date:  2017-03-10       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.